Vivek Subbiah: Our latest publication on pancreatic cancer management with tumor-agnostic precision medicine
about a recent paper by him and Neha Reddy, Heme/Onc Fellow at Northwestern University Feinberg School of Medicine, published in Carcinogenesis:
“Hot off the press. Delighted to share our latest publication: ‘Redefining pancreatic cancer management with tumor-agnostic precision medicine.’
Discover how precision medicine and tumor-agnostic therapies are enhancing outcomes for pancreatic cancer patients.
From KRAS mutations to NTRK and RET fusions and beyond, these therapies offer new hope.
This paper will be published as part of a special issue edited by Dr. Sharon R. Pine and Dr. David Tuveson at Carcinogenesis Oxford University Press.”
“Redefining pancreatic cancer management with tumor-agnostic precision medicine”
Authors: Neha Reddy and Vivek Subbiah.
More posts featuring Vivek Subbiah.
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023